Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast Cancer

Matthew J. Ellis, MD, PhD
Published: Sunday, May 28, 2017


Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Patients often present with a larger breast mass, which puts the patient at high-risk of systemic recurrence, explains Ellis.

There was a subset of patients who did not see positive results with neoadjuvant chemotherapy, allowing neoadjuvant endocrine therapy to be investigated to attempt to shrink the tumor.
 

Matthew J. Ellis, MD, PhD, professor of Oncology and Medicine at Baylor College of Medicine, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Patients often present with a larger breast mass, which puts the patient at high-risk of systemic recurrence, explains Ellis.

There was a subset of patients who did not see positive results with neoadjuvant chemotherapy, allowing neoadjuvant endocrine therapy to be investigated to attempt to shrink the tumor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x